Antiangiogenic activity and cytotoxicity of triterpenoids and homoisoflavonoids from 'Massonia pustulata' and 'Massonia bifolia' by Schwikkard, Sianne et al.
1 
 
Copyright  Thieme Publishing Group. 
 
https://www.thieme-connect.de/DOI/DOI?10.1055/a-0577-5322  
  
2 
 
Antiangiogenic Activity and Cytotoxicity of Triterpenoids and 
Homoisoflavonoids from Massonia pustulata and Massonia bifolia.  
 
 
Sianne L. Schwikkard1,2, Hannah Whitmore2, Timothy W. Corson3, Kamakshi 
Sishtla3, , Moses K. Langat2,4, Mark Carew1 and Dulcie A. Mulholland3,4,* 
 
1 School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston-
upon-Thames, United Kingdom.  
2Natural Products Research Group, Department of Chemistry, Faculty of Engineering 
and Physical Sciences, University of Surrey, Guildford, United Kingdom. 
3Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana 
University School of Medicine, Indianapolis, U.S.A. 
4School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South 
Africa 
 
 
 
 
 
Correspondence 
Professor Dulcie A Mulholland 
Natural Products Research Group 
Department of Chemistry 
University of Surrey 
Guildford, GU27XH 
United Kingdom 
d.mulholland@surrey.ac.uk 
  
3 
 
Abstract:  
The Hyacinthaceae family (sensu APGII) with approximately 900 species in around 70 
genera, plays a significant role in traditional medicine in Africa as well as across 
Europe and the Middle and Far East. The dichloromethane extract of the bulbs of 
Massonia pustulata (Hyacinthaceae sensu APGII) yielded two known 
homoisoflavonoids, (R)-5-hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone 1 
and 5-hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromone 2 and four spirocyclic 
nortriterpenoids, eucosterol 3, 28-hydroxyeucosterol 4 and two previously unreported 
triterpenoid derivatives, (17S,23S)-17α,23-epoxy-3β,22β,29-trihydroxylanost-8-en-
27,23-olide 5 and (17S, 23S)-17α,23-epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-
olide 6.  Compounds 1, 2, 3, and 5 were assessed for cytotoxicity against CaCo-2 cells 
using a neutral red uptake assay.  Compounds 1, 2 and 5 reduced cell viability by 70% 
at concentrations of 30, 100 and 100 μM respectively. Massonia bifolia yielded three 
known homoisoflavonoids, (R)-(4’-hydroxy)-5-hydroxy-7-methoxy-4-chromanone 1, 
(R)-(4’-hydroxy)-5,7-dihydroxy-4-chromanone 7 and (R)-(3’-hydroxy-4’-methoxy)-5,7-
dihydroxy-4-chromanone 9, two previously unreported homoisoflavonoids, (E)-3-
benzylidene-(3’,4’-dihydroxy)-5-hydroxy-7-methoxy-4-chromanone 8 and (R)-(3’,4’-
dihydroxy)-5-hydroxy-7-methoxy-4-chromanone 10, and a spirocyclic nortriterpenoid, 
15-deoxoeucosterol 11.  Compounds 1, 1Ac, 7, 8, 9 and 10 were screened for 
antiangiogenic activity against human retinal microvascular endothelial cells. Some 
compounds showed dose-dependent antiproliferative activity and blocked endothelial 
tube formation, suggestive of antiangiogenic activity. 
 
Keywords: Massonia species, Hyacinthaceae, homoisoflavonoids, spirocyclic 
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Introduction  
The genus Massonia Houttuyn (Hyacinthaceae, subfamily Hyacinthoideae, tribe 
Massonieae) [1] is found in the dry areas of South Africa and southwestern Namibia. 
The genus was named after a Scottish student gardener at Kew, Francis Masson, who 
described the genus while collecting seeds in the Cape in 1772.  The genus is not 
known to be used by traditional healers in the region.  Massonia pustulata, first 
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described in 1791 by Nikolaus von Jacquin, flowers in winter and a dry summer 
dormancy is required.  Massonia bifolia (syn. Whiteheadia bifolia) was originally 
described by von Jacquin in 1791 as Eucomis bifolia, however, the plant was 
‘rediscovered’ as Melanthium massoniifolium in 1804 and as Whiteheadia latifolia in 
1865. It was soon after renamed as Whiteheadia bifolia due to similarities between the 
collected specimen and that described by Jaquin.  It remained the only species in the 
Whiteheadia genus until 2004 when it was transferred to Massonia by Manning et al. 
due to the results of its DNA sequence analysis [2].  This analysis was prompted by 
the discovery of a second species, W. etesionamibensis, which was tentatively placed 
in the Whiteheadia genus.  However, the DNA analysis indicated that this species fell 
between the genera Whiteheadia and Massonia, suggesting it was an evolutionary 
stepping stone from Massonia to Whiteheadia.  As such, Massonia was given a 
broader scope to include Whiteheadia rather than to create a second, new single-
species genus for W. etesionamibensis [3]. The phytochemistry of the genus Massonia 
has not been investigated previously. 
The subfamily Hyacinthoideae (sensu APGII) is characterised by the presence of 
homoisoflavonoids and spirocyclic nortritepenoids, usually of the lanostane type [4].  
Genera from this family are widely used by traditional healers [4] and 
homoisoflavonoids isolated from this subfamily have shown anti-inflammatory activity 
[5-7] and activity against colon (HT-29) and breast cancer (MDA-MB-435) [8,9] cells.  
Spirocyclic nortriterpenoids have shown activity against HeLa cells [10] and HSC-2 
oral squamous carcinoma cells [11-13].  Homoisoflavonoids 1 and 2 and spirocyclic 
nortriterpenoids 3, 4, 5 and 6 were isolated from the dichloromethane extract of the 
bulbs of Massonia pustulata and were assessed for anti-proliferative activity against 
CaCo-2 cells.  Homoisoflavonoids 1, 7, 8, 9 and 10 and the spirocyclic nortriterpenoid 
11 were isolated from the ethanol extract of the bulbs of Massonia bifolia. Compound 
1 was acetylated to aid in separation, forming compound 1Ac.   Since some 
homoisoflavonoids have been shown to have antiangiogenic activity [14- 17], the 
ability of compounds 1, 1Ac, 7, 8, 9 and 10 to block in vitro angiogenesis of human 
retinal microvascular endothelial cells (HRECs) was assessed. Structures are 
provided in Fig. 1. 
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Results and Discussion  
(R)-5-Hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone 1 and 5-hydroxy-3-(4-
hydroxybenzyl)-7-methoxy-4-chromone 2 have been isolated previously from 
Lachenalia rubida Jacq. [18]. This species, like Massonia pustulata, is from the 
subfamily Hyacinthoideae and endemic to the dry areas of South Africa and Namibia.  
(R)-5-Hydroxy-3-(4-hydroxybenzyl)-7-methoxy-4-chromanone 1 has also been 
isolated from Ledebouria graminifolia Bak. (Jessop) [19].  Eucosterol 3 was first 
isolated from Eucomis autumnalis [20] and later from Eucomis bicolor [21],  (17S, 
23S)-23,17-epoxy-3β,28,29-trihydroxy-27-norlanost-8-en-24-one 4 has been isolated 
previously from Eucomis zambesiaca [21], (R)-(4’-hydroxy)-5,7-dihydroxy-4-
chromanone 7 has been extracted from Scilla scilloides [22] , Leopoldia (Muscari) 
comosa [23] and several Ledebouria species [7] and (R)-(3’-hydroxy-4’-methoxy)-5,7-
dihydroxy-4-chromanone 9 has been extracted from Scilla nervosa [9].  15-
Deoxoeucosterol 11 has been isolated from several plant species including Scilla 
scilloides [24] and Pseudoprospero firmifolium [25] .  
      
Compound 5 was isolated as an amorphous white powder.  HR-ESIMS indicated a 
formula of C30H46O6 with [M++1] at m/z = 503.33666 (C30H46O6+H requires 
503.33726). The FTIR spectrum showed absorption peaks at 3391 cm-1 and 1758 cm-
1 due to hydroxyl and carbonyl stretches respectively.  NMR spectra indicated a 
lanosterol-type triterpenoid, with a spirocyclic γ-lactone side chain, typical of the 
subfamily Hyacinthoideae.  The spectroscopic data obtained was very similar to that 
obtained for the co-isolated eucosterol 3.  As with eucosterol, an 8,9-double bond (δc 
134.7 and 134.6 respectively), a 3β-hydroxyl group (δc 80.7 and δH 3.50 dd, J = 6.0Hz 
and 12.2 Hz, W1/2 = 20.3 Hz) [21]  and an oxymethylene group at C-29 (δc 64.3 and δH 
4.27, δH 3.36) were noted.  Four tertiary methyl groups were present at δH 0.94 (3H-
18), δH 0.96 (3H-19), δH 1.25 (3H-28) and δH 2.24 (3H-30), together with two secondary 
methyl group resonances at δH 1.31, (3H-21) and δH 1.39, (3H-26).  The presence of 
the C-17 carbon resonance at δc 99.4 together with C-23 fully substituted carbon 
resonance at δc 115.5 indicated a spirocyclic ring system as shown in Fig 2. [26].  An 
oxymethine proton resonance ascribed to H-22 was noted (δH 3.99), and the 
corresponding carbon resonance (δc 84.0) showed correlations in the HMBC spectrum 
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with the H-21 (δH 1.31) resonance.  Further correlations were seen between the H-22 
(δH 3.99) and C-17 (δc 99.4) resonances, the 3H-26 (δH 1.39) and C-27 (δc 178.8) and 
C-24 (δc 42.0) resonances and the H-24 (δH 2.45) and C-27 (δc 178.8) and C-23 (δc 
115.5) resonances.  A correlation was seen between the 3H-21 (δH 1.31) and H-22 
(δH 3.99) resonances in the NOESY spectrum, indicating the hydroxyl group at C-22 
was β.  The compound was identified as the previously unreported (17S,23S)-17α,23-
epoxy-3β,22β,29-trihydroxylanost-8-en-27,23-olide. 
 
Compound 6 was isolated as an amorphous white powder.  The FTIR spectrum 
showed absorption peaks at 3353 cm-1 and 3250 cm-1 indicative of the presence of 
hydroxyl groups as well as absorption peaks at 1772 cm-1 and 1723 cm-1 indicative of 
carbonyl groups.  The molecular ion was not seen in the LCMS. The NMR data for 
compound 6 was similar to that obtained for compound 5, but differed in showing the 
presence of a keto group at C-3 (δc 213.6), an oxymethylene group at C-28 (δc 63.4) 
and the absence of the hydroxyl group at C-22 (δc 32.3 instead of δc 84.0).  
Correlations were seen in the HMBC spectrum between the H-24α (δH 2.00) and H-
24β (δH 2.72) and C-23 (δc 113.6) resonances, and between 3H-26 (δH 1.28) and C-
25 (δc 35.8) resonances.  Correlations were also noted in the HMBC spectrum 
between the 3H-30 (δH 1.05) and C-8 (δc 133.5) resonances and between the 3-H-19 
(δH 0.98) and C-9 (δc 135.4) resonances.  Various glycoside derivatives of compound 
6 have been isolated from Scilla peruviana [10] but the aglycone, (17S,23S)-17α,23-
epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-olide, has not been reported 
previously.  Key correlations seen in the HMBC spectra of compounds 5 and 6 are 
shown in Fig. 2. 
HR-ESIMS of compound 9 indicated a [M + H]+ ion at m/z 317.1020 corresponding to 
a molecular formula of C17H16O5 for the compound.  The 1H NMR spectrum indicated 
this compound was a 3-benzyl-4-chromanone type homoisoflavonoid due to 
characteristic proton peaks and coupling patterns, including the two H-2 proton 
resonances at δH 4.30 (dd, J=11.3, 4.4 Hz) and δH 4.14 (dd, J=11.3, 7.4 Hz), the H-3 
resonance at δH 2.84 (m) and the two H-9 resonances at δH 3.08 (dd, J=14.4, 5.3 Hz) 
and δH 1.62 (dd, J=14.4, 10.1 Hz).  Also seen in the proton spectrum was a singlet 
peak at δH 3.83 integrating to 3H, indicating that a single methoxy group was present.  
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The C-4 carbonyl carbon resonance was present at δC 200.1 and a H-bonded OH 
group proton resonance was seen at δH 12.10, confirming the placement of a hydroxy 
group at C-5. Two meta-coupled proton resonances were present (δH 6.05, J = 2.3 Hz, 
H-6 and 6.02 J = 2.3 Hz, H-8).  Both resonances showed a correlation with the single 
methoxy group proton resonance in the NOESY spectrum, so a methoxy group was 
placed at C-7. 
The B ring was 1,3,4-trisubstituted as shown by the typical splitting patterns of H-2’ 
(δH 6.70, d, J=2.1 Hz), H-5’ (δH 6.73, d, J = 8.0 Hz) and H-6’ (δH 6.57, dd, J = 8.0, 2.1 
Hz) in the 1H NMR spectrum.  Hydroxy groups were placed at the remaining C- 3’ and 
C-4’ positions. CD analysis confirmed the configuration at C-3 as R due to the negative 
Cotton effect seen at 290 nm [27] and the compound was identified as the previously 
unreported 3R-(3’,4’-dihydroxybenzyl)-5-hydroxy-7-methoxy-4-chromanone. 
Compound 10 was isolated as a brown oil. HR-ESIMS indicated a protonated 
molecular ion at m/z 315.0863 indicating a molecular formula of C17H14O6 for the 
compound. This compound was identified as the E-3-benzylidene homoisoflavonoid 
analogue of compound 9, E-3-(3’,4’-dihydroxybenzylidene)-5-hydroxy-7-methoxy-4-
chromanone. The two equivalent H-2 resonances occurred at δH 5.39 (J=1.8 Hz) and 
the H-9 resonance occurred at δH 7.72 (br s). The E configuration of the double bond 
was confirmed by the characteristic H-9 proton shift. For the E-configuration, H-9 
occurs in the δH 7.58-7.79 region while for the Z-configuration, the H-9 resonance 
occurs at about δH 6.86 [28]. 
Compounds 1, 2, 3 and 5 were assessed for activity against CaCo-2 cells using a 
neutral red uptake assay [29, 30] (Figure 3). Healthy cells take up neutral red into 
lysosomes whereas dead or damaged cells do not. The amount of neutral red 
recovered from cells at the end of the assay (as determined by absorbance) is related 
to the number of viable cells after exposure to a test compound.  Cell viability was 
reduced below 70% by compound 1 at 30 μM and for compounds 2 and 5 at 100 μM.  
Compound 3 had no effect on cell viability.  Compound 2 at 100 μM (p<0.05) was of 
similar activity (22% viability) to actinomycin D (10 μg/mL or 7.96 μM, purchased from 
Sigma-Aldrich cat no: A1410, 98% purity), a known cytotoxic agent, but at 13x 
concentration (Figure 3) Overall, the reported activity was moderate for these 
compounds. 
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Compounds 1, 1Ac and 7-10 were tested for their effect on proliferation of Human 
Retinal Microvascular Endothelial Cell (HRECs) (Figure 4).  GI50 values for the 
compounds, the concentration at which the proliferation of cells is reduced by 50% 
relative to the DMSO control, were calculated and compounds that only reduced cell 
proliferation at the highest concentration tested (relative to DMSO control) were 
reported as having a GI50 > 100 µM. Compound 1 was reported to have the most 
potent GI50 value of 24.8 µM, compounds 7 and 8 were found to have GI50 values of 
35.8 µM and 93.2 µM respectively.  Compounds 1Ac, 9 and 10 had negligible effect 
on cell proliferation.   
We then tested these compounds for anti-angiogenic activity in an in vitro Matrigel 
tube formation assay.  This assay models the endothelial cells’ ability to form vascular 
structures. HRECs overall tubule formation decreased significantly and in a dose-
dependent manner when compared to DMSO (Figure 5).  Compounds 1, 7 and 8 again 
proved most potent of the compounds to block vascular tube formation by HRECs.  
The majority of (synthetic) antiangiogenic homoisoflavonoids described previously 
have trisubstituted A-rings [16], thus the finding that compound 1, disubstituted on this 
ring, had reasonably potent activity is novel. Taken together with previous SAR studies 
on synthetic homoisoflavonoids, these findings help identify homoisoflavonoids that 
could be pursued towards therapies for neovascular eye diseases such as wet age-
related macular degeneration. 
 
Materials and Methods 
General experimental procedures 
Optical rotations were measured at room temperature on a JASCO-P-1020 
polarimeter and IR spectra were recorded using a Perkin-Elmer (2000 FTIR) 
spectrophotometer using KBr windows.  ECD spectra were measured on an Applied 
Photophysics Chirascan CD spectrometer using a 1 mm cell and CH3CN as the 
solvent.  1H, 13C and 2D NMR spectra were recorded on a Bruker AVANCE III NMR 
spectrometer, operating at 500 MHz for 1H and 125 MHz for 13C, using standard 
experiments from the Bruker pulse programs library.  Chemical shifts are reported in 
ppm (δ) referencing the solvent signal (CDCl3) as internal standard respect to TMS (0 
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ppm), and coupling constants (J) are measured in Hz.  HR-ESIMS was performed on 
a Bruker MicroToF Mass Spectrometer, using an Agilent 1100 HPLC to introduce 
samples. Gravity column chromatography was performed using silica gel (Merck Art. 
9385) packed 1 or 4 cm diameter columns. TLC was performed on aluminium 
precoated silica gel plates (Merck 9385) visualised using anisaldehyde spray reagent. 
Mass spectra of compounds 9 and 10 were recorded on a Thermo Q-Exactive Orbitrap 
Mass Spectrometer using direct HESI injection. 
 
Plant material 
Massonia pustulata Jacq. and Massonia bifolia Jacq. bulbs were obtained from the 
collection of the Royal Horticultural Society, Wisley Gardens, Wisley, Surrey, UK 
(W20150204A WSY and W20150850 WSY respectively). 
Extraction and isolation of compounds from M. pustulata and M. bifolia  
The bulbs of Massonia pustulata (672.1 g) were chopped and extracted by shaking 
successively for 24 hours in dichloromethane (CH2Cl2) and then methanol (MeOH) to 
yield 8.35 g of CH2Cl2 extract and 29.67 g of MeOH extract.  The dichloromethane 
extract was fractionated over silica gel starting with EtOAc:CH2Cl2 (1:9) and increasing 
the concentration of EtOAc.  110 fractions of 20 mL each were collected.  Further 
fractionation over Sephadex LH20 (1:1, CH2Cl2:MeOH) yielded compounds 1-6 (20 
mg, 8.9 mg, 50 mg, 15 mg, 4.6 mg and 28 mg respectively). 
Bulbs of Massonia bifolia (263.0 g) were chopped and extracted by shaking for 2x24 
hours in ethanol (EtOH) yielding a combined 5.13 g of extract. The extract was 
fractionated over silica gel, starting with CH2Cl2 as solvent and gradually increasing 
the polarity by addition of use of EtOAc. 95 fractions of 20 mL each were collected. 
Further fractionation over Sephadex LH20 (1:1, CH2Cl2:MeOH) yielded compounds 1 
and 7-11 (19 mg, 9.8 mg, 2.3 mg, 3.2 mg,1.4 mg and 6.9 mg respectively). Structures 
of compounds 1-11 are shown in Fig. 2. 
 
(17S,23S)-17α,23-epoxy-3β,22β,29-trihydroxylanost-8-en-27,23-olide (5): 
Amorphous white solid (4.6 mg, 75% pure; from NMR); [α]D23.6 +44.4, (CHCl3, c = 2.7 
mg/mL); IR  vmax cm-1: 3391, 2934, 1758, 1455, 1375, 1034, 736; 1H- and 13C-NMR 
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(500 MHz, CDCl3) see Table 1. HR-ESI-MS: m/z 503.33667 for [M++H]+ (calcd. for 
C30H47O6, 503.33726) 
 
(17S, 23S)-17α,23-epoxy-28,29-dihydroxylanost-8-en-3-on-27,23-olide (6):  
Amorphous white solid (28 mg, 70% pure from NMR); [α]D23.6 +3.08 (CHCl3, C = 20.3 
mg/mL); IR vmax cm-1: 3353, 3250, 2937, 1772, 1723, 1456, 1371, 1046, 736; 1H- and 
13C-NMR (500 MHz, CDCl3) see Table 1. HR-ESI-MS: M+ not detected. 
 
3R-(3’,4’-dihydroxybenzyl)-5-hydroxy-7-methoxy-4-chromanone (9): cream/brown oil 
(3.2 mg); [α]D20.2 = +67.5 (MeOH, C = 1.6 mg/mL); CD (CH3CN) 256 nm (Δε + 0.25), 
286 nm (Δε – 9.19), 313 nm (Δε + 1.05); IR vmax cm-1: 3349, 2949, 2925, 2848, 1639, 
1449, 1014; 1H- and 13C-NMR (500 MHz, MeOD) see Table 2. HESIMS m/z 317.1020 
[M + H]+, (calcd. for  C17H17O6, 317.1025).  
E-3-(3’,4’-dihydroxybenzylidene)-5-hydroxy-7-methoxy-4-chromanone (10): brown oil 
(1.4 mg); IR vmax cm-1: Insufficient quantity of compound; 1H- and 13C-NMR (500 MHz, 
MeOD). See Table 2. HESIMS m/z 315.0863 [M + H]+, (calcd. for  C17H15O6, 315.0868)  
Pharmacological Assays 
Neutral red assay 
CaCo-2 human colon carcinoma cells (CACO-2 (ECACC 86010202)) from Public 
Health England, UK, were cultured in EMEM (Eagle’s Minimum Essential Medium, 
ATCC/LGC Standards) supplemented with 10% FBS, 2 mM glutamine, 1% non-
essential amino acids, 100 U/mL penicillin/100 U/mL streptomycin, and maintained in 
5% CO2/95% air in an incubator at 37oC.  Cells were plated in 96 well plates at 2x104 
cells/well for 48 hours.  Cells were then treated for 48 hours with one of the following, 
in 4 replicates: culture medium alone (untreated control); 0.1% DMSO (vehicle control; 
maximum DMSO exposed to cells); actinomycin D 10 μg/mL (positive control); test 
substances at 1, 3, 10, 30 and 100 μM (diluted from a 100 mM stock in DMSO).  Cells 
were washed with PBS, and neutral red (25 µg/mL in culture medium, diluted from a 
stock of 2.5 mg/mL in ultrapure water) was added for 3 hours, cells were washed with 
PBS, and neutral red extracted in 50% ethanol/water with 1% acetic acid.  Absorbance 
was read at 540 nm.  Data are reported from 5 independent experiments (different cell 
passages).  The mean absorbance of wells without cells (blank) was subtracted from 
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all other readings.  Plates were accepted for analysis given adequate neutral red 
loading in vehicle treated cells (>0.18 absorbance units) and positive control activity 
(<60% viability); Z factor values were in the range 0.68 to 0.88. Replicates were 
averaged to give one treatment value per plate.  All plate treatment values were 
divided by the mean value of vehicle-treated cells on the same plate, so data was 
normalised as percentage of maximum cell viability.  The plate treatment values were 
averaged to produce group means of n=5.  Analysis of multiple means was performed 
by one way ANOVA with Dunnett’s multiple comparison test against the untreated cells 
(negative control) value, using GraphPad Prism 6.   
 
HREC proliferation assay  
Endothelial Growth Medium (EGM-2) was prepared by mixing the contents of an EGM-
2 “Bullet Kit” (Cat. no. CC-4176) with Endothelial Basal Medium (EBM) (Lonza).  The 
EGM-2 “Bullet Kit” contains hydrocortisone, human fibroblast growth factor (hFGF), 
VEGF, R3-insulin like growth factor (R3-IGF-1), ascorbic acid, human epidermal 
growth factor (hEGF), gentamycin and heparin along with 2% foetal bovine serum 
(FBS).  Human Retinal Endothelial Cells (HRECs) and proprietary Attachment Factor 
were purchased from Cell Systems (Kirkland, WA, USA). HRECs were used for cell 
proliferation studies between passages 5 and 7.  
The base of a tissue culture flask (10 cm2) was washed with 1 mL of attachment factors 
and aspirated. Cryopreserved cells were removed from liquid nitrogen storage and 
defrosted just prior to use.  Cells were transferred into EGM-2 media (5 mL) which was 
then centrifuged (2 mins, 270xg).  The liquid above the cell pellet was aspirated off 
and the cell pellet was resuspended in 10mL EGM-2 and transferred into the flask.  
The tube was then incubated overnight (37°C, 5% CO2) until cells reached confluence.  
Medium was aspirated and the cells washed with PBS (3 mL).  PBS was aspirated 
and 500 µL TrypLE (Life Technologies) added and coated over the surface of the cells 
for a maximum of 30 seconds.  Trypsin was then aspirated and EGM-2 medium (2 mL) 
was added to the tube to wash cells from the surface. The resulting cell slurry was 
transferred to a Falcon tube (15 mL) and diluted with sufficient EGM-2 to seed 
approximately 2,500 cells per well.   
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The required 2,500 cells/well in 100 uL medium were incubated in the centre 48 wells 
of a 96-well clear bottom black plates for 24 hours, with the surrounding 48 wells 
containing 100 µL deionized, sterilised water.  Standard 1:10 dilutions of compounds 
in DMSO ranged from 100 mM to 100 nM such that seven concentrations of each 
compound were tested and the eighth and final well for testing containing DMSO as a 
control.  Cells were treated with 1 µL of different concentrations of each test compound 
and control, resulting in a final in-well concentration range of 1 nM to 1 mM with a final 
DMSO concentration of 1% in all wells.  All compounds were tested in triplicate, and 
our previously-reported synthetic, antiangiogenic homoisoflavonoid SH-11037 [16] 
was included as a positive control. Treated cells were incubated for a further 48 hour 
period.  
At the end of this incubation period, AlamarBlue reagent (11.1 µL) was added and 
after 4 hours of incubation, fluorescence readings were taken with excitation and 
emission wavelengths of 560 nm and 590 nm respectively.  Data were analyzed and 
dose response curves generated using GraphPad Prism software (v. 6.0).     
In vitro Angiogenesis Assay 
A Matrigel based tube formation assay was performed as previously described [31].   
Briefly, 50 µL Matrigel was allowed to solidify in a 96 well black, clear bottom plate at 
37°C for 20 minutes.  HRECs were added to the solid Matrigel at 15,000 cells/well in 
100 µL EGM-2 and dosed with appropriate concentrations of compound with 1 µL 
DMSO/well.  Tube formation was observed every 2 hours by brightfield microscopy 
and images were taken after 8 hours of tube formation.  Six images per treatment were 
analyzed with AngiogenesisAnalyzer plugin for ImageJ [32], and HREC total tubule 
length for treated cells was normalized to DMSO.  Statistical analysis was completed 
using GraphPad Prism.   
 
Supporting information 
Photographs of plant material, spectra for compounds 5, 6, 8 and 10 and graphs 
showing effects of compounds on HREC cell proliferation are available as Supporting 
Information. 
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Fig. 1 Structures of compounds 1 – 11 
 
 
 
 
Fig. 2 Key correlations seen in the HMBC spectra for compounds 5 and 6.  
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Table 1 1H and 13C NMR data for Compounds 5 and 6 (CDCl3).  
 
Compound 
5 
 Compound 6 
No. δC δH (J in Hz) δC δH (J in Hz) 
1 35.3 1.21 m, 1.80 m 34.8 1.25 m, 1.79 m 
2 28.3 1.30 m 35.8 1.75, 1.25 
3 80.7 3.50 dd (6.0, 12.2) 213.6  
4 43.5  48.3  
5 51.2 1.20 m 45.3 1.80 m 
6 18.6 1.50 m, 1.80 m 19.5 1.5 m, 1.8 m 
7 26.4 1.90 m 26.3 2.05 m 
8 134.7  133.5  
9 134.6  135.4  
10 37.4  36.9  
11 20.6 1.99 m, 2.13 m 20.5 1.94, 2.05 
12 24.9 2.23 m, 1.55 m 24.7 1.5, 2.0 m 
13 49.6  46.7  
14 50.6  50.6  
15 32.0 α 1.35 m  
β 1.75 m  
31.3 α 1.38 m 
β 1.68 m 
16 37.7 α 1.85 dd (5.6, 13.4) 
β 2.80 dd (9.1, 13.4) 
36.9 α 1.80 m 
β 2.50 m 
17 99.4  98.3  
18 19.6 0.94 s 18.6 0.90 s 
19 19.8 0.96 s 19.5 0.98 s 
20 50.3 2.30 m 43.7 2.25 m 
21 15.5 1.31 d (6.8)  18.6 1.05 d (6.8) 
22 84.0 3.99 bs (W1/2 = 5.4)  32.3 α 1.80 m 
β 2.55 m 
23 115.5  113.6  
24 42.0 α 2.45 dd (4.5, 7.8), β 2.10 dd (7.8, 
8.0)  
45.2 α 2.00 m, β 2.72 
m 
25 35.5 2.70 m  35.8 2.97 m 
26 16.5 1.39 d (7.4) 15.1 1.28 d (7.0) 
27 178.8  179.6  
28 22.2 1.25 s 63.4 α 4.10 d (12.5) 
β 3.80 d (12.5) 
29 64.3 α 3.36 d (11.2) 
β 4.27 d (11.2) 
70.7 α 3.70 d (14.0) 
β 4.40 d (14.0) 
30 26.0 2.24 s 24.7 1.05 s 
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Table 2 1H and 13C NMR data for Compounds 9 and 10 (CD3OD).  
 Compound 9  Compound 10  
No. 13C 1H (J in Hz) 13C 1H (J in Hz) 
2 70.4 α 4.14 (dd, 11.3, 7.4) 
β 4.30 (dd, 11.3, 4.4) 
68.9 5.39 (d, 1.79) 
3 48.3 2.84 m 127.4  
4 200.1  187.2  
4a 103.8  105.0  
5 165.2  169.6  
6 95.9 6.05 (d, 2.3) 95.7 6.08 (d, 2.3) 
7 169.6  169.5  
8 94.7 6.02 (d, 2.3) 94.7 6.02 (d, 2.3) 
8a 164.8  163.9  
9 33.3 α 3.08 (dd, 14.4, 5.3)  
β 2.62 (dd, 14.4, 10.1) 
139.8 7.72 s 
1’ 131.1  127.0  
2’ 117.3 6.70 (d, 2.1) 118.5 6.86 (d, 2.1) 
3’ 146.7  150.3  
4’ 145.2  163.8  
5’ 116.6 6.73 (d, 8.0) 116.9 6.87 (d, 8.1) 
6’ 121.6 6.57 (dd, 8.0, 2.1) 125.1 6.81 (dd, 8.2, 2.1) 
5-OH (in CDCl3)  12.10 s   
7-OCH3 56.4 3.83 s 56.1 3.84 s 
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Fig 3. Effect of test compounds on Caco-2 proliferation after 48 hours as measured 
by neutral red uptake.  Mean values are shown with SEM.  N=5 independent experiments. 
Effect of positive control (Actinomycin D) was 23% +/- 8% (not shown). * p<0.05 compared 
to DMSO control. 
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Fig. 4 Effect of compounds on HREC cell proliferation, normalised to DMSO control. 
Mean values are shown with SEM, n=3 wells, representative data from at least 
triplicate experiments. Synthetic homoisoflavonoid SH-11037 was positive control. 
 
 
 
 
 
 
  
  
Fig. 5 Tube formation ability of HRECs treated with compounds at 3 concentrations 
(10 µM, 30 µM, and 100 µM) was observed in Matrigel over 8 hours and images 
were taken using brightfield microscopy.  Tubule length was determined using 
ImageJ.  Synthetic homoisoflavonoid SH-11037 was positive control. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001 compared to DMSO, ANOVA with Dunnett’s post hoc tests. 
Mean values are shown with SEM, n=6, representative data from at least triplicate 
experiments.  Images above are tubes formed by HRECs in the presence of 30 µM 
of each compound above, or 100 nM SH-11037 positive control, or DMSO control.  
Scale bars = 500 µm. 
   
